The Regulatory Reality of 2026: What Actually Changed In late 2023, the FDA moved 19 peptides, including BPC-157, to what's known as "Category 2" status under its framework for bulk drug substances used in compounding, identifying them as substances that "may present significant safety risks." The concern, as stated in FDA guidance, centered on the limited large-scale human data and questions about immunogenicity
The publication date of this is 6th March 2024
This will make it much simpler to determine the correct dosage of HGH
The nutritional quality of canola oil and other seed oils can vary depending on the brand and processing method, and some may be produced in a way that minimizes negative health impacts
The effectiveness of oral supplementation depends on how significantly the absorption pathway is compromised
Educational resources explain safe handling and storage after vial opening